Olverembatinib dimesylate
(CAS: 1421783-64-3) |
SKU-Pack Size | Availability | Size | Price | |
EBC51164-1ML | In Stock | 1mL(10mM in DMSO) | €206.70 | |
EBC51164-5MG | In Stock | 5mg | €141.70 | |
EBC51164-10MG | In Stock | 10mg | €258.70 | |
EBC51164-25MG | In Stock | 25mg | €440.70 |
Please Select The Country You Are In To Find Your Local Distributor. |
![]() |
OlaSciences | Phone£º+33 (0) 9 77 4001 556 |
87, rue des Suisses 65000 Nanterre, | E-mail£ºola@olasciences.com | |
France | France | Web£ºwww.olasciences.com |
Product Information | |||||||||||||||||||||
Synonym(s) | GZD824 dimesylate; HQP1351 dimesylate | ||||||||||||||||||||
Chemical Name | 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide dimethanesulfonate | ||||||||||||||||||||
Application | Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. | ||||||||||||||||||||
CAS Number | 1421783-64-3 | ||||||||||||||||||||
Purity | ¡Ý99.0% | ||||||||||||||||||||
Molecular Weight | 724.77 | ||||||||||||||||||||
Molecular Formula | C31H35F3N6O7S2 | ||||||||||||||||||||
SMILES | CC1=CC=C(C(NC2=CC=C(CN3CCN(C)CC3)C(C(F)(F)F)=C2)=O)C=C1C#CC4=CN=C5C(C=NN5)=C4.CS(=O)(O)=O.CS(=O)(O)=O | ||||||||||||||||||||
Target & IC50 | Bcr-AblT315I : IC50=0.68 nM | ||||||||||||||||||||
Solubility | DMSO: 125 mg/mL (172.47 mM)
Water: 50 mg/mL (68.99 mM) |
||||||||||||||||||||
Preparing Stock Solutions |
|
||||||||||||||||||||
Shipping | Gel Pack | ||||||||||||||||||||
Storage | Store at -20¡ãC | ||||||||||||||||||||
Research Use | For Research Use Only. Not Intended for Diagnostic Or Therapeutic Use. |
Product Description | |
Olverembatinib dimesylate also known as GZD824 is an orally bioavailable Bcr-Abl inhibitor. GZD824 exhibited high affinity with Kd values of 0.32 and 0.71 nM for Bcr-AblWT and Bcr-AblT315I, respectively. GZD824 inhibited Bcr-Abl with IC50 values of 0.34, 0.68, 0.27, 0.71, 0.15, 0.35, 0.29 and 0.35 nM for Bcr-AblWT, Bcr-AblT315I, Bcr-AblE255K, Bcr-AblG250E, Bcr-AblQ252H, Bcr-AblH396P, Bcr-AblM351T and Bcr-AblY253F, respectively. In a competitive binding assay, GZD824 bound to the ATP-binding sites of native Abl with Kd values of 0.32 and 0.34 nM for non-phosphorylated and phosphorylated Abl. In stably transformed Ba/F3 cells, GZD824 potently inhibited cells growth with IC50 values of 1.0 and 7.1 nM for Bcr-AblWT and Bcr-AblT315I expressed cells, respectively. |
Specific Protocols | |